Your email has been successfully added to our mailing list.

×
0.0247933884297521 0.0165289256198347 0.0165289256198347 0.0165289256198347 0.0247933884297521 0.0330578512396695 0.0495867768595042 0.0330578512396695
Stock impact report

Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst First 15 Patients with Average Reduction of 24 msec

CYTODYN INC (CYDY) 
NASDAQ:AMEX Investor Relations: ir.cytodyn.com
Company Research Source: Business Wire
The 60 double-blinded arm (700 mg) will be unblinded by early December VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today reported data from its trial treating NASH (nonalcoholic steatohepatitis) open label with leronlimab.Leronlimab open label NASH results continue to show reductions in fat and fibrosis suggestive of a potential therapy not only for NAFLD (Non-Alcoholic Fatty Liver Deposit) but also in NASH. Fat reductions by proton density fat fraction PDFF up to 45% along with reductions in fibrosis up to 8% by CT1 were noted from baseline after just 14 weeks of treatment. The reductions in fibrosis were seen in both severe and mild-moderate NASH cases.Nader Pourhassan, Ph.D., CytoDyn’s President and Chief Executive Officer, stated, “Though numerous drugs have been evaluated in clinical trials, there h Show less Read more
Impact Snapshot
Event Time:
CYDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CYDY alerts
Opt-in for
CYDY alerts

from News Quantified
Opt-in for
CYDY alerts

from News Quantified